Margins on the edge: personal care giants struggle as investors demand more than revenue beats

By early May 2026, Coty was grappling with steep profitability challenges as its operating margin plunged to negative 29%, exacerbated by rising costs, European inventory destocking, and near-total sales halts in the Middle East. Despite a slight revenue beat at $1.28 billion, organic sales fell 7%, reflecting weakening demand and prompting a strategic shift from a 'sell-in' to a 'sellout' model aimed at reducing inventory and regaining market share for brands like CoverGirl and Sally Hansen. Nevertheless, persistent margin pressures and demand headwinds continued to weigh heavily on investor confidence and stock valuation.

Hims & Hers faced a turbulent Q1 2026 marked by a sharp decline in gross margin from 73% to 65% and adjusted EBITDA halving from $91 million to $44 million, resulting in a GAAP net loss of $92 million despite modest 4% revenue growth to $608 million. This profitability squeeze stemmed from higher expenses and a strategic pivot in its weight loss segment from compounded GLP-1 products to branded medications, which compressed margins and challenged monetization as average revenue per user dropped from $85 to $80. Yet, management raised full-year revenue guidance to $2.9 billion and reaffirmed ambitious 2030 targets, signaling confidence in long-term growth despite near-term financial headwinds.

The broader personal care sector exhibited a paradox in Q1 2026: while companies like Herbalife and USANA beat revenue and EBITDA expectations—with Herbalife growing revenues 7.8% to $1.32 billion and USANA posting flat revenues with strong earnings beats—stock prices declined sharply, with Herbalife down over 20% and USANA falling 8.4%. This divergence underscores investor anxiety over profitability sustainability and margin pressures, as Herbalife’s weak EBITDA guidance and USANA’s longer-term revenue and EPS declines (down 1.7% and 19% annually over three years, respectively) cast shadows over their financial outlooks despite solid top-line performance.

Herbalife presents a nuanced financial picture: it boasts an elite 86% gross margin and a five-year average return on invested capital exceeding 50%, highlighting operational efficiency and a best-in-class business model. However, its slow organic revenue growth of just 1.1% over the past eight quarters signals waning demand in core markets, a dynamic reflected in its 14.3% stock price decline over six months, which starkly contrasts with the S&P 500’s 7.8% gain. This tension between strong profitability metrics and sluggish growth continues to fuel investor caution.

Investor sentiment in the personal care and consumer health sector has been notably cautious and volatile throughout mid-2026, with mixed reactions to earnings reports reflecting deeper concerns beyond top-line growth. For instance, Hims & Hers experienced an 11.5% stock drop after missing Q1 revenue estimates despite raising its full-year revenue outlook to $2.9 billion, underscoring investor wariness about margin compression and profitability as adjusted EBITDA guidance fell short of analyst forecasts. This volatility is further highlighted by the stock’s 55% decline over the past year, driven by missed earnings and a GAAP net loss, alongside insider and institutional selling that signals uncertainty about near-term financial pressures and operational execution.

Within the sector, valuation disparities and investor confidence vary widely, reflecting divergent company fundamentals and growth prospects. Coty’s stock has suffered from negative sentiment due to stagnant organic revenue and a 29.3% annual EPS decline, trading at a low forward P/E of around 6–7x, which contrasts sharply with premium valuations for stalwarts like Colgate-Palmolive and Philip Morris. These latter companies command forward P/Es above 21x, justified by strong customer loyalty, high gross margins exceeding 60%, and robust free cash flow generation, which investors reward with greater confidence despite broader sector headwinds.

The broader personal care group’s Q1 earnings painted a paradoxical picture: while revenues beat analyst expectations by roughly 2–2.5%, investor reactions were predominantly negative, with average share prices declining between 1.5% and 5.9% post-earnings. Notably, Herbalife’s stock plunged over 20% following weak EBITDA guidance despite 7.8% revenue growth, and Coty’s shares dropped 13.3% despite modest revenue beats, signaling that profitability concerns and margin pressures weigh heavily on market sentiment. Conversely, Estée Lauder bucked this trend with a 7.2% stock gain after strong EPS and EBITDA beats, illustrating that earnings quality and margin strength remain critical to investor confidence.

Investor caution extends to companies like USANA and Herbalife, where declining revenue and earnings metrics have dampened enthusiasm despite attractive valuations. USANA’s stock has underperformed the S&P 500 over six months, trading at a fair but uninspiring 8.8x forward P/E amid a 19% annual EPS decline and shrinking sales. Herbalife, while suffering a 14.3% stock decline and organic growth concerns, still offers a compelling value proposition with a forward P/E of just 4.4x, supported by elite gross margins near 86% and a five-year average ROIC exceeding 50%, suggesting that value-oriented investors may find opportunity amid the sector’s turbulence.

By early 2026, personal care companies like Coty and Hims & Hers have been recalibrating their strategies to better align with shifting consumer preferences that increasingly favor ethical production, natural ingredients, and trusted brands. Coty’s pivot from a 'sell-in' to a 'sellout' model aims to reduce excess inventory and regain market share for legacy brands such as CoverGirl and Sally Hansen, yet it continues to grapple with margin pressures and demand challenges amid a competitive landscape. Similarly, Hims & Hers is navigating these shifts by moving away from compounded GLP-1 weight loss products toward branded medications, while simultaneously investing in technology, AI, and international expansion to capture evolving telehealth and personal care markets. These strategic responses underscore the tension between adapting to consumer demand for authenticity and innovation and managing near-term financial headwinds.

Despite a collective 2.5% revenue beat in Q1 among nine tracked personal care stocks, the sector has faced a paradoxical decline in share prices, averaging a 1.5% drop post-earnings. This divergence suggests that while companies are successfully tapping into consumer trends toward ethical and natural products, investors remain cautious about future growth prospects and margin sustainability amid intensifying competition and evolving market dynamics. The 2% below-consensus guidance for the next quarter further reflects this cautious outlook, highlighting the ongoing challenge of translating consumer preference shifts into consistent financial performance.